Metraipolis › archive › dc_f9214190aeed

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41160422
DOI
10.1093/ndt/gfaf230
License (as archived)
solo-consultazione
Archived
2026-11-02T22:58:56.695Z
SHA-256 of the archived text
3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305
Stable URL of this page
https://metraipolis.com/documento/dc_f9214190aeed

How to cite

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422 — Europe PMC (en), https://europepmc.org/article/MED/41160422 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f9214190aeed (Metraipolis archive dc_f9214190aeed, sha256 3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305)
BibTeX
@misc{dcf9214190aeed,
  title = {Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease — Europe PMC PMID:41160422},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41160422},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f9214190aeed; sha256 3eb4c81de7cefd2053c9c9ab165f45413ded25641b5bc86895bf34292f952305},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41160422. Agents can read the archived copy with the MCP tool read_document.